723280-91-9

Basic information

• Product Name: 5-(((3-bromophenyl)amino)methylene)-2,2-dimethyl-1,3-dioxane-4,6-dione
• Synonyms: 5-(((3-bromophenyl)amino)methylene)-2,2-dimethyl-1,3-dioxane-4,6-dione
• CAS NO: 723280-91-9
• Molecular Weight: 326.147
• Mol File: 723280-91-9.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: 5-(((3-bromophenyl)amino)methylene)-2,2-dimethyl-1,3-dioxane-4,6-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(((3-bromophenyl)amino)methylene)-2,2-dimethyl-1,3-dioxane-4,6-dione(723280-91-9)
• EPA Substance Registry System: 5-(((3-bromophenyl)amino)methylene)-2,2-dimethyl-1,3-dioxane-4,6-dione(723280-91-9)

Safety Data

• Hazardous Substances Data: 723280-91-9(Hazardous Substances Data)

Upstream product

• 2033-24-1 cycl-isopropylidene malonate 
• 591-19-5 m-Bromoaniline 
• 149-73-5 trimethyl orthoformate 
• 122-51-0 orthoformic acid triethyl ester 
• 15568-85-1 5-methoxymethylene-2,2-dimethyl-1,3-dioxane-4,6-dione 

Downstream Products

• 82121-06-0 7-bromo-4(1H)-oxoquinoline 
• 868374-60-1 1-benzyl-5-bromoquinolin-4(1H)-one 

Relevant articles and documents

COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS

Disclosed herein are compounds of Formula (I) which inhibit, regulate and/or modulate tyrosine kinase receptors, particularly Axl and Mer signal transduction pathways related to the changes in cellular activities, compositions containing the compounds, methods of using the compounds to treat kinase-dependent diseases and conditions, and methods for making the compounds.

Synthesis of novel halogenated 4(1H)-quinolones by thermolysis of arylaminomethylene-1,3-dioxane-4,6-diones

A variety of novel 4(1H)-quinolone derivatives were prepared by thermolysis of aminomethylene Meldrum's acid derivatives. Georg Thieme Verlag Stuttgart.

COMPOUND HAVING TGF-BETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION CONTAINING SAME

The present invention provides compounds of formula (I) or compounds of formula (II) and pharmaceutically acceptable salts or solvates thereof. An objective of the present invention is to provide compounds having TGF2 inhibitory activity.